Entinostat (MS-275)

Catalog No.S1053

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Entinostat (MS-275) Chemical Structure

Entinostat (MS-275) Chemical Structure
Molecular Weight: 376.41

Validation & Quality Control

Cited by 61 publications:

14 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Entinostat (MS-275) is available in the following compound libraries:

HDAC Inhibitors with Unique Features

Product Information

  • Compare HDAC Inhibitors
    Compare HDAC Products
  • Research Area

Product Description

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
IC50 0.51 μM 1.7 μM
In vitro MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SCC-3M2HVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\QemNKSzVyPUCuNFYyKM7:TR?=NV\KeGdIW0GQR1XS
ALL-POMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTBwME[zOVUh|ryPMnrMV2FPT0WU
697Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PGc2lEPTB;MD6wPVk4PiEQvF2=MlLaV2FPT0WU
NCI-H748MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPOTWM2OD1yLkGwN|M1KM7:TR?=MmXaV2FPT0WU
NKM-1Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXBZWNKSzVyPUCuNVA6OTJizszNMUDTRW5ITVJ?
ES1NH;KdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTBwMUGyOVUh|ryPM3X3bHNCVkeHUh?=
NCI-H1963Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvXWXlVUUN3ME2wMlEyPTd7IN88US=>NUe1UYo2W0GQR1XS
NCI-H1417M4TQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDiTWM2OD1yLkGyPVc1KM7:TR?=MX;TRW5ITVJ?
NEC8NIizbWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETSN5JKSzVyPUCuNVM2OjdizszNMlezV2FPT0WU
CRO-AP2MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\CUWlEPTB;MD6xOlg5QSEQvF2=MUPTRW5ITVJ?
A3-KAWNUDsSHJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fYUmlEPTB;MD6xO|YzPyEQvF2=MYjTRW5ITVJ?
SF539MkH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTBwMUm1PVMh|ryPMWnTRW5ITVJ?
NOS-1NVOzSJN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{XCZWlEPTB;MD6xPVYyQSEQvF2=NVjrXI81W0GQR1XS
NTERA-S-cl-D1MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjyZpZxUUN3ME2wMlIxOTF|IN88US=>MVjTRW5ITVJ?
COR-L88MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYPjTZJXUUN3ME2wMlIzQTV7IN88US=>MkD2V2FPT0WU
EM-2M1zpdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTBwMkSwO|kh|ryPNF2wRXlUSU6JRWK=
KARPAS-45NHTqe3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTBwMke4N|Mh|ryPMne0V2FPT0WU
DSH1MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTBwMki3NFgh|ryPMl\5V2FPT0WU
HT-144NWLIOIpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvETJJ3UUN3ME2wMlMxOjV4IN88US=>NHrY[IZUSU6JRWK=
ATN-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\rR3k6UUN3ME2wMlMxPTd4IN88US=>NIToRnNUSU6JRWK=
HELMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk[4TWM2OD1yLkOxN|Q5KM7:TR?=NV7KVY9{W0GQR1XS
NB12M2W4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTBwM{G3OVYh|ryPNHfkOXdUSU6JRWK=
LU-139NV;3ZmM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITCd|RKSzVyPUCuN|M2OSEQvF2=Mo\ZV2FPT0WU
J-RT3-T3-5NHXyUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUOzVFhNUUN3ME2wMlM{PzF4IN88US=>NFnrTphUSU6JRWK=
MOLT-13MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HscmlEPTB;MD6zN|gyKM7:TR?=NUDLeZFJW0GQR1XS
SRMlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\MRmxNUUN3ME2wMlM1OjZzIN88US=>NIT3UWNUSU6JRWK=
CMKM2TaVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTBwM{W3Nlch|ryPMXjTRW5ITVJ?
ES8M1rwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PKSGlEPTB;MD6zOlAzOiEQvF2=MU\TRW5ITVJ?
LB647-SCLCNHvZd2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn3MTWM2OD1yLkO2O|Mh|ryPMVjTRW5ITVJ?
TE-8MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXUTWM2OD1yLkO2PVM2KM7:TR?=MnTaV2FPT0WU
BV-173MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPZcFNMUUN3ME2wMlM4OTJzIN88US=>NF2zRlJUSU6JRWK=
DELNWXV[4dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTBwM{e0PFch|ryPNVmzbmJSW0GQR1XS
ARH-77NVjCc3FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVy1cnZlUUN3ME2wMlM5OTl|IN88US=>NXqwTmFVW0GQR1XS
NCCITMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTER|dHUUN3ME2wMlM5PjR7IN88US=>NV3TbmNUW0GQR1XS
RPMI-8402MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXjWoRKSzVyPUCuN|g4ODFizszNMVvTRW5ITVJ?
MONO-MAC-6NY[zbXN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3BTWM2OD1yLkO4O|c3KM7:TR?=MXXTRW5ITVJ?
SK-MM-2MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\L[m15UUN3ME2wMlM6QDZ6IN88US=>NUns[4Y3W0GQR1XS
CHP-126Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnKTWM2OD1yLkSwNlMyKM7:TR?=Ml3hV2FPT0WU
A101DNF7qc3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rK[WlEPTB;MD60NFMh|ryPNWnOPVl4W0GQR1XS
SCHMkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzaTWM2OD1yLkSwN|QzKM7:TR?=NYTPVWRCW0GQR1XS
NMC-G1MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1rse2lEPTB;MD60NFM3PyEQvF2=NFn0[VdUSU6JRWK=
NCI-H209NVXlZlB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLTN5dKSzVyPUCuOFA3OTNizszNMWDTRW5ITVJ?
MOLT-16M4jhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXThNG9SUUN3ME2wMlQyODF5IN88US=>NFTUU|JUSU6JRWK=
RPMI-6666NEH3dm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{W5SWlEPTB;MD60NVEzKM7:TR?=MUTTRW5ITVJ?
OPM-2NUTVcpp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2S4PGlEPTB;MD60NVUyOyEQvF2=NUPadIFOW0GQR1XS
MRK-nu-1MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MojaTWM2OD1yLkSzNVU{KM7:TR?=MXvTRW5ITVJ?
BC-1NFfwNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXuyfndnUUN3ME2wMlQ{PDB|IN88US=>M{fjOnNCVkeHUh?=
MHH-NB-11M4DGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1ny[2lEPTB;MD60N|Q2OyEQvF2=M13yTXNCVkeHUh?=
Ramos-2G6-4C10NWHzPGxlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnSyTWM2OD1yLkSzPFk4KM7:TR?=NIXEfJJUSU6JRWK=
LS-513MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHqxPHVKSzVyPUCuOFQ2ODFizszNMUPTRW5ITVJ?
K5MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXSSIE1UUN3ME2wMlQ4ODJ3IN88US=>NWHodpU2W0GQR1XS
HOP-62NX3SW|ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHy2R2lKSzVyPUCuOFg{PThizszNNGOzc3VUSU6JRWK=
NCI-H187M4H2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DUNWlEPTB;MD60PVIzPyEQvF2=NWXSXmp[W0GQR1XS
BE-13NHOyPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4Pxe2lEPTB;MD60PVY3OSEQvF2=NGTNTnVUSU6JRWK=
HC-1NY\jXpZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnf4TWM2OD1yLkWwOFc{KM7:TR?=MkjCV2FPT0WU
ACNNHvlTJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXq5W4xMUUN3ME2wMlUyODJ6IN88US=>NXmwem1HW0GQR1XS
HCC1599MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPPbZhKSzVyPUCuOVE2PyEQvF2=M3zz[HNCVkeHUh?=
MV-4-11NX7YSXVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TxbGlEPTB;MD61N|A1OSEQvF2=MYfTRW5ITVJ?
LC-2-adM1r0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTBwNUO2OlMh|ryPMkfHV2FPT0WU
HL-60NYSxcVRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlznTWM2OD1yLkW0NlYyKM7:TR?=NX3jeoVRW0GQR1XS
NB17MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DCZ2lEPTB;MD61OFM5KM7:TR?=MlmyV2FPT0WU
TE-1NXvYWGFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\Sd4hXUUN3ME2wMlU2OzB4IN88US=>MYrTRW5ITVJ?
NCI-H524MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTBwNUW0NFEh|ryPNUX6eHRHW0GQR1XS
MZ7-melNFLXOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfubnNKSzVyPUCuOVYyODVizszNNXTJTGtKW0GQR1XS
L-363MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTBwNU[2OVch|ryPMmDJV2FPT0WU
BL-41MnjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGG2V2tKSzVyPUCuOVY5QDlizszNMXLTRW5ITVJ?
LU-134-ANGP0RnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnq2TWM2OD1yLkW3NFc{KM7:TR?=NHLpOnFUSU6JRWK=
SIG-M5NIq1TmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUOy[|lSUUN3ME2wMlU4QDR6IN88US=>NEP3WJhUSU6JRWK=
ONS-76MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXOTWM2OD1yLkW4NlQzKM7:TR?=MXzTRW5ITVJ?
KARPAS-299MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\rU2lEPTB;MD61PFUxPCEQvF2=M{jzWnNCVkeHUh?=
DU-4475MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXuwbHk{UUN3ME2wMlU5PzB|IN88US=>NX\V[4NEW0GQR1XS
NB69MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTxSWNKSzVyPUCuOVk5OjVizszNMWTTRW5ITVJ?
MHH-PREB-1MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXrlNpM5UUN3ME2wMlYxPzF7IN88US=>MXXTRW5ITVJ?
LU-165MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LIT2lEPTB;MD62NVgyOiEQvF2=NEjk[VhUSU6JRWK=
LOUCYM2fuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTBwNkOzOlQh|ryPNFK4dolUSU6JRWK=
NCI-H526NFW5SWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTBwNkO1OFEh|ryPMlP3V2FPT0WU
KE-37MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\WbWlEPTB;MD62OFI4PiEQvF2=MlXaV2FPT0WU
NALM-6M1jVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDyU|g{UUN3ME2wMlY1QDZizszNNHLBZYdUSU6JRWK=
CW-2NHL5eHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3PNXJYUUN3ME2wMlY2Pzl2IN88US=>M3vPUXNCVkeHUh?=
SU-DHL-1Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXLN2xFUUN3ME2wMlY2QTR5IN88US=>M{jtW3NCVkeHUh?=
NB13MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXq0XZp1UUN3ME2wMlY3QDF5IN88US=>M3f2WHNCVkeHUh?=
QIMR-WILNUP3TZI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;P[mlEPTB;MD62PFM1OyEQvF2=NXzBU|ZiW0GQR1XS
ECC12NHG0Z5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTBwN{CwPFYh|ryPMV;TRW5ITVJ?
KALS-1NX;vW5VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUfufoY1UUN3ME2wMlcxPDl{IN88US=>MXrTRW5ITVJ?
COR-L279M3vk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzITWM2OD1yLkewPVk3KM7:TR?=MUDTRW5ITVJ?
NB14M3u4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPJTWM2OD1yLkeyOlE4KM7:TR?=MYnTRW5ITVJ?
CCRF-CEMMn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF62XoJKSzVyPUCuO|Q3PjFizszNMXzTRW5ITVJ?
SW954MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkOwTWM2OD1yLke1PVk6KM7:TR?=NWT4S4w5W0GQR1XS
IST-SL1MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LyR2lEPTB;MD63O|M1QCEQvF2=MnTFV2FPT0WU
LAMA-84MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjVRlFTUUN3ME2wMlc4PTZ5IN88US=>M{jDUnNCVkeHUh?=
DaudiM2LJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTHTWM2OD1yLke3OlgyKM7:TR?=NWLJNJpWW0GQR1XS
BC-3M{nBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LleWlEPTB;MD63PFMxQCEQvF2=Mn22V2FPT0WU
HCC2998NFL0SYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGr2[nFKSzVyPUCuO|g{PiEQvF2=Mly5V2FPT0WU
NCI-H69NXHrSI1MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLNTWM2OD1yLkiwNVQ4KM7:TR?=MYLTRW5ITVJ?
CPC-NNIXNXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDOU2FDUUN3ME2wMlgxPTJ2IN88US=>MkjWV2FPT0WU
NOMO-1MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTBwOEGwPFQh|ryPMl\VV2FPT0WU
CESSNE\lWIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTBwOEGxPVch|ryPNWXSfHN3W0GQR1XS
LC4-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XTXmlEPTB;MD64OFAxPyEQvF2=NYTEUJdLW0GQR1XS
BL-70NX\3[WRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHUTWM2OD1yLki1O|AzKM7:TR?=MXPTRW5ITVJ?
ES4MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDx[nJKSzVyPUCuPFU5PjhizszNM4PJd3NCVkeHUh?=
HCE-TMl6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFnGe2ZKSzVyPUCuPFcyPzFizszNMoG5V2FPT0WU
JARMl\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTBwOEe4Nlch|ryPNWXYOpd6W0GQR1XS
ST486NIXJSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTNTWM2OD1yLki3PVE4KM7:TR?=M3nN[3NCVkeHUh?=
KS-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LNXGlEPTB;MD64PFA6PiEQvF2=NIjUXVZUSU6JRWK=
GDM-1Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DXWmlEPTB;MD64PFY5PyEQvF2=MUHTRW5ITVJ?
EHEBNGTiNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTBwOUK1PFUh|ryPNHLKTGhUSU6JRWK=
LB2518-MELMkLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTBwOUOyPFQh|ryPNIXmeVFUSU6JRWK=
GOTOMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3m0VmlEPTB;MD65OVA4PiEQvF2=MXXTRW5ITVJ?
LXF-289NHP3TXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1:4VmlEPTB;MD65OVkxOSEQvF2=Mk\hV2FPT0WU
ES6M4jCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3GfFBPUUN3ME2wMlk3PDN5IN88US=>MUnTRW5ITVJ?
OS-RC-2Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTBwOU[4N{DPxE1?NUDwXGtWW0GQR1XS
DMS-153MnvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzBO5VKSzVyPUCuPVc1PjlizszNMV\TRW5ITVJ?
SK-PN-DWMk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTBwOUe4N|Eh|ryPM3GxXnNCVkeHUh?=
HHMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1Pw[WlEPTB;MD65PFk2QSEQvF2=M13uPXNCVkeHUh?=
SH-4M4jJVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXKxPJRHUUN3ME2xMlAzPDFizszNNHjoVlBUSU6JRWK=
MOLT-4MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTFwMEO0OVQh|ryPNVPifGFOW0GQR1XS
TGWMnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\zc2piUUN3ME2xMlA4Pjd3IN88US=>NWHsPIE5W0GQR1XS
L-540Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXiNI5KSzVyPUGuNVA3ODRizszNNES3Z4xUSU6JRWK=
PF-382M4rxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17sRWlEPTB;MT6xNVUyOyEQvF2=MnXjV2FPT0WU
LC-1FMnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jFNGlEPTB;MT6xNlAxPyEQvF2=NH:0fJNUSU6JRWK=
OVCAR-4MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnnTIVUUUN3ME2xMlE{OTZ3IN88US=>M4PyRXNCVkeHUh?=
A4-FukMlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLafGRDUUN3ME2xMlE2OzZ2IN88US=>NEHUSXpUSU6JRWK=
HCC2218Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDTTJgxUUN3ME2xMlE3PjRzIN88US=>MW\TRW5ITVJ?
HAL-01Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHIUG9KSzVyPUGuNVY6PDNizszNMVfTRW5ITVJ?
IST-MEL1M3n5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzuVJhvUUN3ME2xMlE4PjV7IN88US=>NVjaR3FnW0GQR1XS
NCI-H719MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3PSRWlEPTB;MT6xO|g6QCEQvF2=NV65T2dmW0GQR1XS
EVSA-TMk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrCc5ZKSzVyPUGuNVgyOTRizszNNETESGNUSU6JRWK=
SK-NEP-1NV;Rc29yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TkZWlEPTB;MT6yNFI3PiEQvF2=M{\uWnNCVkeHUh?=
OCUB-MMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTFwMkG0PFkh|ryPNVT4R|FMW0GQR1XS
MEG-01M1:zV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfPZppKSzVyPUGuNlIyOThizszNMoLNV2FPT0WU
no-10M{jMRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTFwMkOxNVIh|ryPNFvDN3hUSU6JRWK=
MHH-CALL-2MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLDToszUUN3ME2xMlI1PzJzIN88US=>NUn2OpVNW0GQR1XS
SK-N-DZMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DM[mlEPTB;MT6yOFc4PiEQvF2=MlzmV2FPT0WU
SCLC-21HMnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1foRmlEPTB;MT6yOlQ4QCEQvF2=M3PQcHNCVkeHUh?=
CTV-1NX\u[oN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTFwMke0NlUh|ryPNVnLWIxpW0GQR1XS
NB1MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTFwMke3N|Ih|ryPMkTOV2FPT0WU
NCI-H64MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DHSWlEPTB;MT6yPFQ3OiEQvF2=NHTPUJJUSU6JRWK=
MDA-MB-134-VIMo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPBTWc4UUN3ME2xMlI5PTd5IN88US=>Ml3YV2FPT0WU
LB2241-RCCMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mof0TWM2OD1zLkK4OlY{KM7:TR?=NFfESHRUSU6JRWK=
8-MG-BANF\mV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTFwMki4OlYh|ryPM4TZcXNCVkeHUh?=
LP-1MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{X4U2lEPTB;MT6yPVk1PyEQvF2=NEfXPXlUSU6JRWK=
LS-411NMojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrHS4h{UUN3ME2xMlMxQTl6IN88US=>M1;4V3NCVkeHUh?=
CAL-148M2roSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDjWJhoUUN3ME2xMlMzPTR{IN88US=>MmTrV2FPT0WU
NCI-H2171NVr4T4xYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\xTWM2OD1zLkO0OVAzKM7:TR?=Mn;uV2FPT0WU
JiyoyeP-2003Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHRO4hKSzVyPUGuN|U{QSEQvF2=NXXGOFJIW0GQR1XS
NCI-H2107M1PRVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHHd|dKSzVyPUGuN|U5QDNizszNNYXHOotTW0GQR1XS
BB30-HNCMkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTFwM{i5O|gh|ryPMYTTRW5ITVJ?
K-562MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nRcWlEPTB;MT6zPVIyQSEQvF2=M1fxNHNCVkeHUh?=
PSN1Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17P[mlEPTB;MT60NlI5PyEQvF2=MnXJV2FPT0WU
HCC2157NF3xbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrZTWM2OD1zLkSyOlkyKM7:TR?=MoDUV2FPT0WU
SBC-1NGDCV|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWWyXo5WUUN3ME2xMlQzPzRzIN88US=>M4P6cXNCVkeHUh?=
MC116MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTFwNEO2NVUh|ryPMXrTRW5ITVJ?
KARPAS-422MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XwcmlEPTB;MT60OVM2QCEQvF2=MUHTRW5ITVJ?
LB996-RCCMnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlGxTWM2OD1zLkS3NVA{KM7:TR?=MnfnV2FPT0WU
MSTO-211HMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXj0Z45OUUN3ME2xMlQ4QTh5IN88US=>M{DCeXNCVkeHUh?=
BT-474NXLKO2FoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTFwNUG3OlQh|ryPM{joWnNCVkeHUh?=
A388NYfxZ3JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7hTpRvUUN3ME2xMlUyQTR3IN88US=>MYPTRW5ITVJ?
SJSA-1NIe1fGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzEZ4xrUUN3ME2xMlUzOjZizszNMlz0V2FPT0WU
COLO-829NWLJXnBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIG5RpBKSzVyPUGuOVM2PjRizszNMXjTRW5ITVJ?
KM-H2NXrXWnpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M165TmlEPTB;MT61OlY4KM7:TR?=NFiyT|BUSU6JRWK=
GR-STNGXreodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUGwVVFzUUN3ME2xMlU3QDJizszNMoLTV2FPT0WU
RPMI-8866NHfWe|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHpTWlYUUN3ME2xMlYxOTR2IN88US=>M1H2O3NCVkeHUh?=
KG-1NXvqTWhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTFwNkG5NFEh|ryPM2\QfXNCVkeHUh?=
NCI-H82M2DFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;YbINQUUN3ME2xMlY{PDB4IN88US=>Mlr2V2FPT0WU
LB1047-RCCNWDYeVkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mle5TWM2OD1zLk[zOFU6KM7:TR?=NUfaU|dVW0GQR1XS
KM12M3L0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfqWnVKSzVyPUGuOlQ4KM7:TR?=MWnTRW5ITVJ?
NB5M2LqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTFwNkW2O|ch|ryPM3SyeHNCVkeHUh?=
HDLM-2M2W4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTFwNkiyPFEh|ryPMoTqV2FPT0WU
KU812Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rZdGlEPTB;MT62PVYxPSEQvF2=MXTTRW5ITVJ?
DBMkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4ewZ2lEPTB;MT63NFM2OyEQvF2=MXPTRW5ITVJ?
HD-MY-ZNIW3W4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1m4PGlEPTB;MT63OVI{PCEQvF2=NUPt[|BvW0GQR1XS
KURAMOCHINIXPSppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTFwN{eyNFch|ryPMXnTRW5ITVJ?
ETK-1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHTTWM2OD1zLke4PFc6KM7:TR?=NEjnWoFUSU6JRWK=
SK-UT-1NX\wNXdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jtdWlEPTB;MT63PVM5QCEQvF2=NGHaXI1USU6JRWK=
HUTU-80MlO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jmS2lEPTB;MT63PVUxQCEQvF2=M2rSbXNCVkeHUh?=
ES7MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{jkNWlEPTB;MT64NFMxOiEQvF2=MoTMV2FPT0WU
SW872M3vGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTFwOEGzPVUh|ryPNEXR[4dUSU6JRWK=
TK10NFnqUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTFwOEOxNFgh|ryPNV\weJAzW0GQR1XS
LB831-BLCMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHLfGMyUUN3ME2xMlg{PTZ|IN88US=>NUTZSVRiW0GQR1XS
TE-9NYHZ[GI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXCTWM2OD1zLki0OFIzKM7:TR?=MVTTRW5ITVJ?
MLMAMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLrTWdTUUN3ME2xMlg5OjN2IN88US=>Mn\WV2FPT0WU
D-542MGMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1q2XWlEPTB;MT64PVM4OyEQvF2=NHzoRndUSU6JRWK=
EW-16NYG1bY4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTFwOUK3NkDPxE1?MYLTRW5ITVJ?
LOXIMVIM{HrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHrdJlDUUN3ME2xMlk{OjhizszNM1\UOXNCVkeHUh?=
GB-1NHnHT|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFn1OWZKSzVyPUGuPVM5PjZizszNNHO4WYtUSU6JRWK=
IST-SL2NXnhNJVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVrqe5A1UUN3ME2yMlAxOjZ{IN88US=>Mn3rV2FPT0WU
LAN-6NI[wXHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTJwMEG5OlYh|ryPMn7HV2FPT0WU
NCI-H510ANF;RSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;EeXpKSzVyPUKuNFQ2ODJizszNNXrsW4dMW0GQR1XS
NCI-H1092MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTJwMEWxNlQh|ryPNYDzOG9VW0GQR1XS
HTNFvuO2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXpWVdKSzVyPUKuNVA1PTRizszNNXz0NotvW0GQR1XS
RL95-2Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjYTnpKUUN3ME2yMlEyPDh{IN88US=>MYTTRW5ITVJ?
NCI-H1355M3L2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUPJR|UxRTJwMUG3PVIh|ryPNIrZR3pUSU6JRWK=
NCI-H720M2jjdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTJwMU[4O|Mh|ryPMnTwV2FPT0WU
NCI-H1522MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHvVoJKSzVyPUKuNlE4OjNizszNNGLrWXBUSU6JRWK=
LB373-MEL-DMo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\icG9ZUUN3ME2yMlI3QTB{IN88US=>M{XQS3NCVkeHUh?=
DG-75NIXDOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;sRWlEPTB;Mj6yO|E1QCEQvF2=NYPzXppUW0GQR1XS
ML-2M3rFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3DfXVKSzVyPUKuN|I5PTVizszNNFfKNmVUSU6JRWK=
SF126NGK3NZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTJwM{OwPVQh|ryPMYXTRW5ITVJ?
MPP-89MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIC5bYlKSzVyPUKuN|MyPDVizszNMmLTV2FPT0WU
NCI-H345NF70VmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTJwM{OyO|ch|ryPM3v6NXNCVkeHUh?=
LS-123MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXBVHRKSzVyPUKuN|Q6OzZizszNMXXTRW5ITVJ?
NB10M{jqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M125fGlEPTB;Mj60NVA6OiEQvF2=NIHlWYlUSU6JRWK=
CGTH-W-1NWPjdpUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXYTWM2OD1{LkSyNlY4KM7:TR?=MX3TRW5ITVJ?
CP66-MELNWHJdotIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1v0T2lEPTB;Mj60O|c4KM7:TR?=NWnWdolNW0GQR1XS
L-428M3PTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1O1NWlEPTB;Mj60PFUzOSEQvF2=M4DyO3NCVkeHUh?=
DMS-79NXmzfGp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTETWM2OD1{LkW0NVA{KM7:TR?=NYjvXmRXW0GQR1XS
NCI-H1882MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\STWM2OD1{Lk[3OVYzKM7:TR?=NUTGWYdFW0GQR1XS
KGNMknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUTqVWp3UUN3ME2yMlc3QDd4IN88US=>MVrTRW5ITVJ?
EW-1NUPDbmtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX2wPGVVUUN3ME2yMlc4ODh|IN88US=>MYHTRW5ITVJ?
U-266NILpdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rJT2lEPTB;Mj64OFgzOyEQvF2=NEK2dYdUSU6JRWK=
COLO-320-HSRNWXvO2Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XqPGlEPTB;Mj64OVY1OSEQvF2=NXTRTFJQW0GQR1XS
KMOE-2M3X4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHic|RKSzVyPUKuPFc4OTFizszNNFjMWFJUSU6JRWK=
BB49-HNCNGjj[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLnW5psUUN3ME2yMlkzPDhizszNM{PRO3NCVkeHUh?=
GI-1NWe2SoNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWf5OY5GUUN3ME2yMlkzQTV5IN88US=>NVfTeldzW0GQR1XS
NCI-H1304NXu5bnBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPpbnBOUUN3ME2zMlAxPTFzIN88US=>Mn;iV2FPT0WU
NCI-H2227NULPT|JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTNwMEKwO|kh|ryPM17oOnNCVkeHUh?=
U-87-MGMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTNwMEO1NVMh|ryPMlvqV2FPT0WU
NCI-H747NIPnXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTNwMEWyNFYh|ryPNGLrUFVUSU6JRWK=
CTB-1MkXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTNwMEWzO|Yh|ryPNXv6[VB7W0GQR1XS
RPMI-8226NYnpfnVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzxTWM2OD1|LkG0N|c5KM7:TR?=NX;GZ|RVW0GQR1XS
NCI-H2141MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTNwMU[1OlYh|ryPM3fMe3NCVkeHUh?=
IST-MES1M4K2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXMR4Y{UUN3ME2zMlE5Ojd7IN88US=>M1TTcHNCVkeHUh?=
TE-5NYTVUnBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\ybJpKSzVyPUOuNlE{PDJizszNNV64fFVNW0GQR1XS
UACC-257NGHMSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTNwNEO2OVkh|ryPMUPTRW5ITVJ?
SK-N-FIMnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nRWWlEPTB;Mz60OVIzPyEQvF2=M{W2[HNCVkeHUh?=
MFH-inoNVrsSFROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;tZo9KSzVyPUOuOFY2QDlizszNNFXOVIRUSU6JRWK=
SF268MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTNwNEixO|Qh|ryPM2W3OHNCVkeHUh?=
TE-12NIXmdJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2L3NWlEPTB;Mz61NVY6QSEQvF2=NWHZb|FQW0GQR1XS
NB6MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTNwNUW1OlMh|ryPM4XLOHNCVkeHUh?=
DJM-1M4S4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjOTWM2OD1|LkW5PFk6KM7:TR?=MUXTRW5ITVJ?
MZ1-PCMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfQcIJKSzVyPUOuOlE3OjRizszNMn3wV2FPT0WU
OCI-AML2NWLON2puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXwVIRjUUN3ME2zMlYzPjdzIN88US=>Mmr4V2FPT0WU
NCI-H1155NGfzXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HHe2lEPTB;Mz63NFk1PyEQvF2=M2K3W3NCVkeHUh?=
RKOMl\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33WWWlEPTB;Mz63O|E5QSEQvF2=NUSzXo9EW0GQR1XS
ECC4MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITHTpNKSzVyPUOuPVcyQTVizszNM1npTnNCVkeHUh?=
BB65-RCCNIjMWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkmxTWM2OD1|Lkm3OVQ4KM7:TR?=MYTTRW5ITVJ?
EB-3Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjHTnJKSzVyPUOuPVk3OzNizszNNFjNSHNUSU6JRWK=
SHP-77NVPwNZBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvjTXpKSzVyPUSuNFA2OjRizszNMnKyV2FPT0WU
NCI-H2196MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\GNWlEPTB;ND6wOVYzPSEQvF2=MWnTRW5ITVJ?
GI-ME-NMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHndIVKSzVyPUSuNFY{QTlizszNMWXTRW5ITVJ?
MN-60MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;j[mlEPTB;ND6xNFg4KM7:TR?=MknEV2FPT0WU
NCI-H1694MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDNTWM2OD12LkGzOFA2KM7:TR?=M2riO3NCVkeHUh?=
LU-65M{LOd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXfROpN1UUN3ME20MlE2OzN{IN88US=>NV62eXFqW0GQR1XS
NCI-H1436NE\TSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWKweIF3UUN3ME20MlE5OzN|IN88US=>M1nxVnNCVkeHUh?=
KINGS-1MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoW2TWM2OD12LkOxOFMzKM7:TR?=NYXKTJJIW0GQR1XS
GT3TKBM{Pv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\QTWM2OD12LkOzNlY5KM7:TR?=M1;jO3NCVkeHUh?=
BeckerMlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLaTmxQUUN3ME20MlM4OzF{IN88US=>MmDqV2FPT0WU
HCC1187M4\YZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;lTWM2OD12Lki5OlU4KM7:TR?=MorwV2FPT0WU
D-502MGMkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVT4S2tIUUN3ME21MlAxPDF4IN88US=>MoDZV2FPT0WU
VA-ES-BJNHrJeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrGTWM2OD13LkGzO|c5KM7:TR?=MnLMV2FPT0WU
NB7MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\OfnFqUUN3ME21MlE1OTF{IN88US=>MUTTRW5ITVJ?
SW962NXfVdnN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTVwM{i4NVQh|ryPMljDV2FPT0WU
no-11M{T5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXu5N2F4UUN3ME21Mlc3OzR|IN88US=>MnPKV2FPT0WU
KNS-81-FDNH7W[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTVwOUC2PVQh|ryPMWPTRW5ITVJ?
COLO-684M{PFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHTWPJBKSzVyPUWuPVk1QTRizszNNUfCO|dFW0GQR1XS
D-263MGMnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\HTWM2OD14LkC4PFk2KM7:TR?=NUj5XG1QW0GQR1XS
EW-24NVzJOIZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7LZplKSzVyPU[uNlg2OSEQvF2=M2n3dXNCVkeHUh?=
TE-10NVKzOYpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTZwNEK2NlMh|ryPMoXjV2FPT0WU
EKVXM2TiVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHzIT3RKSzVyPU[uOFY{OjFizszNMVHTRW5ITVJ?
NCI-H1648M{HafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTZwNke1OVch|ryPNV;4TVU4W0GQR1XS
LB771-HNCNWDyTJJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTZwOUKzNFEh|ryPMnzPV2FPT0WU
SK-MEL-1MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzF[mJlUUN3ME24MlE{OTZ4IN88US=>MmrJV2FPT0WU
COLO-668NXWzem5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoL3TWM2OD16LkK3O|g3KM7:TR?=NV;HTmlqW0GQR1XS
EW-12NHzNXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPmTWM2OD16LkSwPFA{KM7:TR?=M{L1UHNCVkeHUh?=
A253NX7xW2Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFKxdpRKSzVyPUiuPFQ3PjFizszNNEPi[lFUSU6JRWK=
NCI-H2126NWrnV5ViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTz[IRKSzVyPUiuPFk{OTlizszNM4fVOHNCVkeHUh?=
Calu-6MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M12xPGlEPTB;OD65PVA1OiEQvF2=NHzB[mxUSU6JRWK=
NCI-H23MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjGTWM2OD17LkG3O|Q3KM7:TR?=NHzhbo1USU6JRWK=
WSU-NHLM2fWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF74Z4xKSzVyPUmuO|c1PzhizszNMYrTRW5ITVJ?
MMAC-SFMn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRTlwOUe5NFQh|ryPM3[0NHNCVkeHUh?=
SK-LMS-1M1\NWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWG0OHdRUUN3ME2xNE4zQDN2IN88US=>NYrOToFOW0GQR1XS
GCIYNFfuRXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\sRmlEPTB;MUCuOVkzPCEQvF2=NIjUdYZUSU6JRWK=
TE-15NUi3ZmhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU[3[5l[UUN3ME2xNU43ODB2IN88US=>MXPTRW5ITVJ?
EoL-1-cellNV34XFNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXuW2ZVUUN3ME2xNU44Pjh{IN88US=>NXOxXZJqW0GQR1XS
NCI-H2081MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTFzLke3PFYh|ryPM2TYcnNCVkeHUh?=
EW-3MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{GyN2lEPTB;MUKuNlQ3OyEQvF2=Mn;MV2FPT0WU
CAS-1MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGS2fmNKSzVyPUGyMlM3OzFizszNNGfWUmNUSU6JRWK=
C2BBe1MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTF{Lk[xN|Eh|ryPMYnTRW5ITVJ?
D-247MGNIjnPIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVzCfmlCUUN3ME2xNk44QTV{IN88US=>NH\mfnFUSU6JRWK=
NCI-SNU-5MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LEVGlEPTB;MUKuPFAyOyEQvF2=M{TIVXNCVkeHUh?=
LS-1034MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHoTWM2OD1zND6zPVc2KM7:TR?=NEDaNVNUSU6JRWK=
EW-18MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTF2LkS0PEDPxE1?MnjNV2FPT0WU
RajiMmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NESyW|FKSzVyPUG0MlUxPDlizszNNHTDTXhUSU6JRWK=
D-283MEDM3S1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTF2Lk[yO|Eh|ryPNXj1SIJZW0GQR1XS
MZ2-MELNGHBS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXRZpRKSzVyPUG0Mlk3QTZizszNMlfRV2FPT0WU
NCI-SNU-16MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjCOYE{UUN3ME2xOU41PjN|IN88US=>M4CzdXNCVkeHUh?=
P30-OHKM1HDPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTF5Lke4N|Eh|ryPMoroV2FPT0WU
RXF393M3T2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDLTWM2OD1zOT6wNVg3KM7:TR?=NHK4S|FUSU6JRWK=
NCI-H1395MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTsVlhKSzVyPUKwMlY4ODNizszNMYPTRW5ITVJ?
U-698-MNFfPc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvm[FlKSzVyPUKwMlcxPzVizszNNEnzdoJUSU6JRWK=
NCI-SNU-1M4DleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTJyLkeyNlMh|ryPM{juTXNCVkeHUh?=
SW684NVjVXo9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTJzLkG3NVYh|ryPNUj5Um5OW0GQR1XS
NCI-H716NInyZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTJzLkOxOVQh|ryPMo\sV2FPT0WU
JVM-2NWjFUJoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF2zXpBKSzVyPUKxMlQyOzNizszNNIfPcJJUSU6JRWK=
NCI-H1581M2PiUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;a[2lEPTB;MkKuOFE1QCEQvF2=M{LCcXNCVkeHUh?=
CA46NXfTO2NPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTNzLk[5N|Yh|ryPNHXuNHJUSU6JRWK=
SNB75MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1Hmc2lEPTB;M{OuOlUxOyEQvF2=NEHKSmFUSU6JRWK=
KNS-42MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTN3Lkm2NlQh|ryPNXHHNFN{W0GQR1XS
TURMl\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILrToVKSzVyPUO2MlA2OjFizszNMYfTRW5ITVJ?
REHNGHkT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTVRYQ{UUN3ME2zO{45OjFzIN88US=>M1PMN3NCVkeHUh?=
EW-22NXXKOII5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHzXZlKSzVyPUSyMlI5QDVizszNNXvWbGpjW0GQR1XS
NCI-H446MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1P0eWlEPTB;NEKuO|g2OyEQvF2=MYDTRW5ITVJ?
ES3M37ZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnr4TWM2OD12Mz6xN|M6KM7:TR?=MlTOV2FPT0WU
EW-11MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M320fmlEPTB;NESuPFIyQCEQvF2=Mk\2V2FPT0WU
RH-1MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvTTWM2OD12Nz61PFEzKM7:TR?=NGC0OoJUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]
Features

Protocol(Only for Reference)

Kinase Assay:

[6]

Standard HDAC Assays Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.

Cell Assay:

[2]

Cell lines A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
Concentrations ~ 10 μM
Incubation Time 3 days
Method

Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.

Animal Study:

[1]

Animal Models A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
Formulation Dissolved with 0.05 N HCl, 0.1% Tween 80
Dosages 12.3, 24.5 and 49 mg/kg
Administration Administered orally once daily 5 days per week for 4 weeks

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Saito A, et al. Proc Natl Acad Sci U S A, 1999, 96(8), 4592-4597.

[2] Sugawara T, et al. 95th AACR, Orlando, 2004, Abst#2451

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02780804 Not yet recruiting Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplas  ...more Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) March 2017 Phase 1
NCT02833155 Not yet recruiting Breast Cancer EddingPharm Oncology Co., LTD. July 2016 Phase 1
NCT02820961 Recruiting Breast Cancer|Estrogen Receptor Positive Breast Cancer Syndax Pharmaceuticals June 2016 Phase 1
NCT02697630 Not yet recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax P  ...more Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals June 2016 Phase 2
NCT02708680 Not yet recruiting Breast Cancer Syndax Pharmaceuticals|Roche Pharma AG April 2016 Phase 1|Phase 2

view more

Chemical Information

Download Entinostat (MS-275) SDF
Molecular Weight (MW) 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms SNDX-275
Solubility (25°C) * In vitro DMSO 75 mg/mL (199.25 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300 10mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name pyridin-3-ylmethyl 4-((2-aminophenyl)carbamoyl)benzylcarbamate

Frequently Asked Questions

  • Question 1
    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

    Answer: 2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related HDAC Products

  • LMK-235

    LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.

  • CAY10603

    CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.

  • 4SC-202

    4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.

  • Panobinostat (LBH589)

    Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

  • Vorinostat (SAHA, MK0683)

    Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

  • Trichostatin A (TSA)

    Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

    Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

  • RGFP966

    RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.

  • Tubastatin A

    Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).

  • Mocetinostat (MGCD0103)

    Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Recently Viewed Items

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us